Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Breast Cancer Research

Figure 4

From: Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

Figure 4

Frequency of the 17q25.3 gain in different subgroups of breast cancers. The genome of 20 luminal A (LumA), 22 luminal B, 21 human epidermal growth factor 2-positive (HER2+), 15 sporadic triple-negative breast cancer (TNBC), 9 BRCA1-mutated non-triple-negative (TN) breast cancers (7 LumA and 2 HER2+), as well as the genome of 23 BRCA1-mutated and 21 non-mutated TNBC was analyzed by array comparative genomic hybridization (array CGH). The presence of the 17q25.3 gain was assessed in these tumors on the basis of the individual array CGH aberration profile analysis.

Back to article page